Karuna Therapeutics to Announce Second Quarter 2023 Financial Results and Provide General Business Update on Thursday, August 3, 2023Business Wire • 07/20/23
Karuna Therapeutics to Present at the Goldman Sachs 44th Annual Global Healthcare ConferenceBusiness Wire • 05/30/23
Karuna Therapeutics to Present Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the American Society of Clinical Psychopharmacology Annual MeetingBusiness Wire • 05/22/23
Karuna Therapeutics Reports First Quarter 2023 Financial Results and Provides General Business UpdatesBusiness Wire • 05/04/23
Karuna Therapeutics to Announce First Quarter 2023 Financial Results and Provide General Business Update on Thursday, May 4, 2023Business Wire • 04/20/23
Karuna Therapeutics Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional SharesBusiness Wire • 03/24/23
Karuna's stock is up after schizophrenia drugs meets primary endpoint in clinical trialMarket Watch • 03/20/23
Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-3 Trial of KarXT in SchizophreniaBusiness Wire • 03/20/23
Karuna Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Result and Provides General Business UpdatesBusiness Wire • 02/23/23
Karuna Therapeutics to Present at the SVB Securities Global Biopharma ConferenceBusiness Wire • 02/09/23
Karuna Therapeutics Announces Exclusive Global License Agreement for Goldfinch Bio's Investigational TRPC4/5 Product CandidatesBusiness Wire • 02/02/23